Author Archives: Julia Black

Dr. Eric Jonasch and Dr. Lizzie Perdeaux elected to IKCC Board of Directors

PRESS RELEASE

7th Expanding Circles 2017 Annual Conference of the International Kidney Cancer Coalition (IKCC): Dr. Eric Jonasch and Dr. Lizzie Perdeaux elected to Board of Directors

The International Kidney Cancer Coalition (IKCC) completed its 7th Expanding Circles 2017 Annual Conference from April 6th – 8th, 2017 in Warsaw, Poland and announces Dr. Eric Jonasch and Dr. Lizzie Perdeaux as new members of the Board of Directors.

Warsaw/Poland, April 20, 2017

The International Kidney Cancer Coalition (IKCC) held its “7th Expanding Circles 2017 Annual Conference – the International Conference for Organisations Representing Patients with Kidney Cancer” from April 6th-8th, 2017 in Warsaw

read more

IKCC Conference, Warsaw, Poland

Our seventh IKCC Conference for kidney cancer patient organisations recently held in Warsaw, Poland was a huge success. The first ever Global Kidney Cancer Awareness Day – Thursday 22nd June 2017 – was officially launched following the keynote address on the ‘Global Burden of Kidney Cancer’ delivered by Prof. Dr. Hendrik van Poppel of Belgium.

During the AGM, Dr. Eric Jonasch, an internationally recognized expert specialising in kidney cancer from Texas, USA and Dr. Elizabeth Perdeaux

read more

IKCC Conference, 6th – 8th April 2017, Warsaw, Poland

7th International Kidney Cancer Coalition Conference

Warsaw, Poland 6th, 7th & 8th April 2017

 Our seventh IKCC Conference for kidney cancer patient organisations will be held in Warsaw, Poland on 6th, 7th & 8th April 2017.

Our conference will bring together cancer patient group leaders from around the world to share best practices, exchange experiences and work together to improve the lives of kidney cancer patients wherever they live. Read more

The main goals of our conference will

read more

Sonepcizumab shows promise for metastatic kidney cancer

Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. <a href="http://www.healio.com/hematology-oncology/genitourinary-cancer/news/in-the-journals/%7B8d65ed95-3a09-4f92-bd0e-1487c53a7d19%7D/sonepcizumab-shows-promise-for-metastatic-renal-cell-carcinoma

read more